PAX5 and precursor B-cell acute lymphoblastic leukemia: Based on these findings, Pax5+/− mice treated with ruxolitinib-containing chow for 28 days early in life eliminate preleukemic cells in vivo and thus avoid B-ALL development compared to mice fed with control chow (71) (Figure 2).